secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064413
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma shareholders approve 5M share increase to equity plan; elect two directors
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2015 Stock Plan, increasing share reserve by 5,000,000 to 15,719,300 shares.
- Incentive stock option term extended to February 26, 2035.
- Class I directors Paul Schimmel and Sara L. Zaknoen elected with 56.6M and 49.0M votes for, respectively.
- Ratification of Ernst & Young as auditor for FY2025 approved (68.9M for, 175K against).
- Advisory vote on named executive officer compensation approved (55.2M for, 1.35M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017025064413/0000950170-25-064413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017025064413/atyr-20240522.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer